Name* Last Name* Email* Phone Number* Town \ Province* —Please choose one option—AlmeriaGranadaJaen Workplace* Indicate the name of the Principal Investigator* Are you a researcher with healthcare activity?* —Please choose one option—YesNo Indicate the name of the collaborating company/s* Does it belong to ibs.GRANADA? * —Please choose one option—SiNo If your answer is yes, indicate the group to which you belong —Please choose one option—A01-TECHNOLOGY APPLIED TO ONCOLOGY AND GENE THERAPYA02-CUIDATE: ONCOLOGY CARE AND ADVANCES IN SPORTS MEDICINEA03-BIOACTIVE MOLECULESA04-DIGITAL AND COMPUTATIONAL PATHOLOGY, IMMUNOPATHOLOGY AND CANCERA06-CLINICAL ONCOLOGY AND LIQUID BIOPSYA08-IMMUNE RESPONSE AND CANCERA09-GENETICS AND MOLECULAR ONCOLOGYA11-MEDICAL PHYSICSA13-CUSTOM ONCOLOGYA15-BASIC AND CLINICAL ONCOLOGYA17-CANCER EPIDEMIOLOGYAe21-EPIGENETICS IN AGING AND CANCERAe22-CANCER GENETICS, BIOMARKERS AND EXPERIMENTAL THERAPIESAE23-TRANSLATIONAL AND INTEGRATIVE ONCOLOGYE03-PHYSIOTHERAPY IN PRIMARY CAREE04-DENTAL PUBLIC HEALTHE05-BIO-ENVIRONMENTAL PSYCHIATRYE06-GENDER, HEALTH AND HEALTH SERVICESE07-RESEARCH IN ENVIRONMENTAL HEALTH AND CHILDRENE08-PARTICIPATORY HEALTHE09-HEALTH AND GENDERE13-STUDY AND CONTROL OF ORAL BIOFILME14-PREVENTIVE MEDICINE AND PUBLIC HEALTHE15-EXPODIET: FOOD EXPOSURE TO ENVIRONMENTAL CONTAMINANTSE16-EMERGING AND TRANSLATIONAL MICROBIOLOGYE17-PULMONOLOGY: ADVANCED ANALYTICS AND THERAPYEe02-RESEARCH IN PRIMARY CARE (GDIAP)Ee11-IMMUNEMEDIATED SKIN DISEASESEE12-HYGIA: CARE AND HEALTH DETERMINING FACTORSEe18-DATA SCIENCE AND ARTIFICIAL INTELLIGENCE FOR MEDICINE AND HEALTHEe19-TOXICOLOGYMP02-CARDIOVASCULAR PHARMACOLOGYMP03-INTERNAL MEDICINE - HVN INVESTIGAMP04-IMMUNOGENETICS SYSTEMIC AND CUTANEOUS DISEASESMPE05-TRANSLATIONAL RESEARCH IN CARDIOVASCULAR DISEASESMP06-CLINICAL NEUROSCIENCESMP07-BASES PHYSIOPATHOLOGY AND MEDICAL THERAPEUTICSMP08-BIOMARKERS HT AND KIDNEY DYSFUNCTIONMP09-NEUROPHARMACOLOGY OF PAINMP10-TRANSLATIONAL BIOINFORMATICSMP11-RHEUMATOLOGYMP12-OTOLOGY AND OTONEUROLOGYMP13-RESISTANCE TO ANTIRETROVIRALSMP14-INFECTIOUS DISEASES. HIVMP15-LIVER DISEASES AND COLORECTAL CANCERMP16-INTESTINAL IMMUNOMODULATIONMP17-INTERCELLULAR COMMUNICATIONMP18-UROMET AND URONCOLOGYMP19-NUTRITION AND METABOLISM IN CHILDHOODMP20-BIOMARKERS OF METABOLIC AND BONE DISEASESMP22-BIOCHEMISTRY OF NUTRITION. THERAPEUTIC IMPLICATIONSMP23-CRITICAL PATHOLOGYMPe24-NEW DIAGNOSTIC AND THERAPEUTIC STRATEGIES IN PREVALENT CARDIOVASCULAR DISEASESMPe25-GRANADA VISION AND EYE RESEARCH TEAM (G-VERT)MPe26-ITEM: TRANSLATIONAL RESEARCH IN MINORITY DISEASESTEC01-SAFE PRACTICE IN THE USE OF MEDICATIONSTEC02-HOSPITAL PHARMACOTHERAPEUTIC MONITORINGTEC03-TISSUE ENGINEERINGTEC04-NANOELECTRONICSTEC05-PHYSICS OF INTERPHASES AND COLLOIDAL SYSTEMSTEC09-OPTICS OF BIOMATERIALS AND TISSUESTEC12-MATERNAL FETAL HEALTH AND ELASTOGRAPHYTEC13-ADVANCED SURGERYTEC14-HUMAN REPRODUCTION AND HEREDITARY AND COMPLEX DISEASESTEC15-NUCLEAR AND MOLECULAR MEDICINETEC16-ADVANCED THERAPIES: DIFFERENTIATION, REGENERATION AND CANCERTEC17-BIOTECH HEALTHTECE18-NANOCHEMBIOTECE19-CLINICAL AND TRANSLATIONAL DERMATOLOGYTECE20-REHABILITA-TTECE21-BONE REPAIR, REGENERATION AND REPLACEMENTTECe22-ADVANCED MEDICAL IMAGINGTEC23-LABORATORY FOR RESEARCH IN INTENSIVE MEDICINE AND MEDICAL EDUCATIONTEC24-HEMATERGE: HEMATOLOGY AND GENE THERAPYTECe25-PHARMACOLOGY AND BIOCHEMISTRY OF IMMUNE-MEDIATED DISEASES AND EXTRACORPOREAL MEDICINE (FarbioQEm)TECHNOLOGICAL PLATFORMSINTERNATIONAL Proposal Summary* (maximum one page indicating IP, group, thematic area, strategic lines, brief summary of the project, type of participation and autonomous communities that will participate in the project) Select the thematic area in which you will present your project: Development of technological platforms, medical imaging, biomarkers and medical devices that allow early diagnosis and clinical and scientific monitoring of people at home, with special attention to the identification of frailty, cognitive deterioration, early diagnosis of diseases related to aging, exacerbation of chronic diseases and control of adverse drug effectsDevelopment and clinical validation of medical devices aimed at reducing health risks in frail elderly people or at risk of frailty and their integration into personalized precision medicine systemsDevelopment and clinical validation of health technology for casual screening, non-specialized management, for use in non-conventional health spaces and its subsequent integration into conventional care processes to respond to unmet clinical needs in frail elderly people or at risk of frailty, in association with developments related to personalized precision medicineDevelopment and clinical validation in the National Health System of technology aimed at home health care for people with high dependency or extreme old age, and its integration with personalized precision medicine systemsDevelopment and full regulatory validation of biomarkers for chronic and oncological diseases, which combine the possibility of being detectable by non-invasive imaging techniques or in easily accessible organic fluids or tissues and the characteristic of being linked to a pharmacologically actionable molecular targetValidation of frailty biomarkers, for diagnostic, therapeutic, rehabilitation or monitoring purposes, in large population samples or in complementary cohortsResearch and development of advanced therapy drugs aimed at elderly patients with chronic and oncological diseases, or frail populations or those at risk of frailtyInnovative tools aimed at improving the precision or simplification of surgical techniques in this populationHealth technology aimed at the early rehabilitation of elderly patients with chronic diseases or frail people or people at risk of frailty, with a precision medicine perspective I have read and agree to the Privacy Policy*
